USANA Health Sciences, Inc. develops and manufactures nutritional supplements, functional foods, and personal care products. The company operates through two main reportable segments: Core Nutritional and Hiya direct-to-consumer. Its core business involves selling science-based nutritional, personal care, and skincare products primarily through a direct selling channel involving independent Brand Partners and Preferred Customers. The company also operates Hiya, a direct-to-consumer provider of children's health and wellness products sold via subscription models, and Rise, which manufactures protein bars and drinks. USANA serves customers in 25 geographic markets worldwide, with Mainland China representing its largest market. The company utilizes an omni-channel platform that includes direct selling, direct-to-consumer sales, third-party marketplaces, and retail channels. Founded in 1992, the company acquired Hiya Health Products in 2024 and Rise in 2022 to expand its product offerings and distribution methods.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Household & Personal Products Homepage usana.com
Sector Consumer Defensive IR page ir.usana.com
Tags
nutritional supplements, functional foods, personal care, skincare, direct selling, direct-to-consumer, children's health, protein products, subscription model, cellular nutrition, Hiya, Rise, Oola, Usanimals, Whey Protein Isolate, Postbiotic Skincare
Press page ir.usana.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 267.362M
Market cap (USD) $ 267.362M
P/E -12.92
PEG —
P/BV 0.51
P/S 0.30
P/OCF 6.42
P/FCF 9.05
Dividend yield —
Turnover / mcap —
Returns  
ROE 2.0%
ROI 2.0%
ROIC 3.4%
Profit margin 1.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -46.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score -5.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 925.257M 854.503M 921.01M 998.601M 1.186B 1.135B 1.061B 1.189B 1.047B 1.006B 918.499M 790.471M 718.175M 648.726M 581.939M 517.644M 517.644M — 423.149M 374.19M 327.742M — — 133.776M 114.28M 123.18M 129.386M
Net profit 10.76M 42.03M 63.788M 69.35M 116.505M 124.664M 100.526M 126.224M 62.535M 100.041M 94.672M 76.636M 79.024M 66.433M 50.752M 45.651M 45.651M — 45.317M 41.266M 38.994M 30.777M 20.817M 8.503M 2.199M 2.867M 5.901M
Free cash flow 8.526M 50.919M 56.147M 93.502M 108.464M 145.307M 110.164M 140.686M 110.563M 104.332M 87.737M 84.764M 90.842M 84.373M 59.465M 61.916M 61.916M — 30.955M 49.482M 43.707M 31.231M 30.914M 12.977M 3.349M -1.197M 10.032M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 19.63 35.89 53.6 53.2 101.2 77.1 78.55 117.73 74.05 61.2 127.75 102.59 75.58 32.92 35 43.33 31.2 36.18 40.66 50.1 — — — — — — —
Price performance 12m -0.45 -0.33 0.01 -0.47 0.31 -0.02 -0.33 0.59 0.21 -0.52 0.25 0.36 1.3 -0.06 -0.19 0.39 -0.14 -0.11 -0.19 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — — — — 4.29M
Lease liabilities (USD) — — — 25.6M 8.62M 7.08M 14.6M 12.4M 16.2M 18M
Cash and deposits (USD) 176M 247M 214M 235M 312M 240M 288M 330M 182M 158M
Intangible assets (USD) 34.3M 35.2M 31.8M 29.8M 30.8M 30.4M 32.4M 29.9M 152M 133M
Right-of-use assets (USD) — — — 31.3M — 23.8M 20M 17.7M 21.2M 23M
Cash flow detail
Operating cash flow (USD) 137M 124M 152M 127M 160M 121M 104M 70.6M 61M 22.3M
Purchases of property, plant and equipment (USD) -32.7M -13.2M -11.4M -16.6M -15.1M -12.8M -10.4M -14.5M -10.1M -13.8M
Change in inventories (cash effect) (USD) -1.03M 6.05M -23.1M 13M -16.8M -10.5M 21.9M 2.35M -2.12M -34.7M
Change in payables (cash effect) (USD) -1.34M 3.04M -1.72M 1.84M 6.08M -4.57M -2.66M -428,000 -1.27M 5.2M
Share buybacks (cash effect) (USD) -64.6M -50M -105M -150M -57M -178M -25.4M -11.6M -9.44M -27.5M
Interest paid (cash effect) (USD) -323,000 -16,000 -6,000 -11,000 -711,000 -10,000 -49,000 -68,000 -76,000 -663,000
Income taxes paid (cash effect) (USD) -52.6M -46M -70.7M -54.9M -53M -59.5M -45.9M -44.2M -40.5M -37.2M
Share-based compensation (USD) 16.5M 15.5M 15M 15.5M 14.4M 14.3M 13.3M 14.6M 14.6M 13.8M
Free cash flow (OCF - PPE - intangibles) (USD) 104M 111M 141M 110M 145M 108M 93.5M 56.1M 50.9M 8.53M
Income detail
Research and development expense (USD) 8.84M 8.95M 10.2M 10.3M 10.6M 11.1M 11.6M 11.4M 11.6M 10.7M
↳ 5y CAGR +16.8% +13.9% +15.0% +14.9% +10.6% +4.7% +5.3% +2.2% +2.4% +0.1%
Total comprehensive income (USD) 92.2M 72.8M 117M 97M 135M 121M 56.1M 62.9M 33.1M 18M
Comprehensive income to owners (USD) 92.2M 72.8M 117M 97M 135M 121M 56.1M 62.9M 33.1M 17.3M
Reported Mar 1, 2017 Feb 28, 2018 Feb 26, 2019 Feb 25, 2020 Mar 1, 2022 Feb 28, 2023 Feb 28, 2023 Feb 27, 2024 Mar 12, 2025 May 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nov 4, 2026 • 11:00am EST

Earnings Release

PDF HTML

Audio

Earnings Webcast

Management Commentary

PDF

© 2026 USANA Health Sciences, Inc. All Rights Reserved.

Accessibility Privacy Policy Disclaimer Sitemap

Follow USANA

  • facebook

  • twitter

  • pinterest

  • youtube

  • instagram

  • wordpress

Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .

Download as PDF November 03, 2026

Independent testing provides third-party validation of USANA's commitment to product quality and label accuracy

SALT LAKE CITY, Nov. 3, 2026 /PRNewswire/ -- USANA Health Sciences (NYSE: USNA), a global leader in cellular nutrition, announced that its BiOmega omega-3 supplement has once again earned the ConsumerLab Seal of Approval, providing independent validation of the company's longstanding commitment to product quality, purity and label accuracy.

ConsumerLab Seal of Approval

USANA voluntarily submitted BiOmega to ConsumerLab's Quality Certification Program, where it underwent the same testing applied to omega-3 products independently selected by ConsumerLab for its 2026 Fish Oil, Krill Oil, and Algal Oil Omega-3 Supplements Review. BiOmega passed ConsumerLab's testing and earned its Seal of Approval.

"Quality has been at the center of USANA from the beginning, and independent testing helps validate the standards we set for ourselves," said Dr. Kathryn Armstrong, chief scientific officer at USANA Health Sciences. "We rigorously test our products, ingredients and manufacturing processes, and third-party verification gives consumers another level of confidence in the quality of the products they choose."

**Quality Consumers Can Verify
**BiOmega is a potent fish oil concentrate fortified with vitamin D and formulated with EPA and DHA, two long-chain omega-3 fatty acids that support cardiovascular, immune and joint health.*

ConsumerLab independently evaluates health and nutrition products for quality, purity and label accuracy. Its 2026 omega-3 review found differences among omega-3 products, including differences in EPA and DHA concentration and freshness. BiOmega met ConsumerLab's quality standards and earned approval, continuing a history of independent recognition for the product that spans multiple ConsumerLab review cycles.

"Consumers should be able to feel confident that the products they choose meet the standards promised on the label," said Brent Neidig, chief commercial officer at USANA. "Quality has been a priority at USANA for more than 30 years, from the science behind our formulations to how our products are manufactured and tested. Independent recognition like the ConsumerLab Seal of Approval provides another level of validation of the standards we set for ourselves."

**A Broader Commitment to Independent Verification
**BiOmega is one of seven USANA products currently approved by ConsumerLab through its Quality Certification Program, with independently tested products spanning omega-3s, multivitamins and minerals, probiotics, vitamin D and protein.

Third-party testing complements USANA's own quality program. The company manufactures its nutritional supplements in an FDA-registered, GMP-certified facility in Salt Lake City, where each batch is tested to meet USANA's standards for quality, purity and potency. That internal testing—combined with continued investment in research, state-of-the-art manufacturing and gold-standard testing protocols—is what independent programs such as ConsumerLab's verify.

BiOmega has a history of earning independent recognition from ConsumerLab. In 2016, the product earned the organization's Seal of Approval after testing confirmed it contained 100 percent of its claimed amounts of EPA, DHA and total omega-3s and met ConsumerLab's quality levels for lead, arsenic, cadmium and mercury.

To learn more about USANA BiOmega and USANA's commitment to product quality, visit USANA.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

**About USANA Health Sciences
**USANA (NYSE: USNA) has been providing premium-quality nutrition and lifestyle products for more than 30 years. From its award-winning supplements manufactured in its FDA-registered facility to its cutting-edge Celavive® skincare and healthy living products, USANA is committed to empowering people to live healthy, vibrant lives. USANA products are trusted by elite athletes, Olympians, and health-conscious consumers in more than 25 countries worldwide.

Learn more at USANA.com  or explore the science behind USANA products at AskTheScientists.com .

Media Contact:
(801) 954-7626
media(at)USANAinc(dot)com

USANA logo.

View original content to download multimedia:https://www.prnewswire.com/news-releases/usana-biomega-earns-consumerlab-seal-of-approval-for-quality-and-purity-302921913.html

SOURCE USANA Health Sciences Inc.

Released November 3, 2026

© 2026 USANA Health Sciences, Inc. All Rights Reserved.

Accessibility Privacy Policy Disclaimer Sitemap

Follow USANA

  • facebook

  • twitter

  • pinterest

  • youtube

  • instagram

  • wordpress

Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .

Download as PDF November 03, 2026

Related Documents

Audio

Earnings Webcast

Management Commentary

PDF

Hiya Active Monthly Subscribers Increase 18% Sequentially; Core Nutritional Operating Margin Expands; Company Generates $36 Million in Year-to-Date Free Cash Flow

SALT LAKE CITY--(BUSINESS WIRE)-- USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 3, 2026.

Key Financial Results

Third Quarter 2026 vs. Third Quarter 2025

  • Net sales of $206 million versus $214 million.
  • Net loss of $(5.6) million versus $(6.5) million.
  • Diluted EPS of $(0.30) as compared with $(0.36).
  • Adjusted diluted EPS(1) of $(0.11) as compared with $(0.15).
  • Adjusted EBITDA(2) of $12.1 million versus $13.8 million.
  • Core Nutritional Active Customers of 356,000 versus 388,000.
  • Hiya Active Monthly Subscribers of 195,500 versus 193,400.
  • Company updates fiscal 2026 guidance to net sales approaching $900 million and Adjusted EBITDA(2) of $77 million.

Q3 2026 Consolidated Performance

Q3 2026 Year-Over-Year Sequentially
Net Sales $206 million -4% (+$4 million or +2% FX impact) -8%
Net Loss* $(5.6) million N/A N/A
Diluted EPS $(0.30) N/A N/A
Adjusted Diluted EPS(1) $(0.11) N/A N/A
Adjusted EBITDA(2) $12.1 million -13% -44%
*Income tax expense of $6 million added to a pretax loss of $(1) million for Q3 2026.
Net Loss, EPS and EBITDA figures represent amounts attributable to USANA and exclude the noncontrolling interest of 21.2% in Hiya.

“As we continue our transformation to an omnichannel health and wellness company, our third quarter results were mixed, with meaningful improvement in some areas and results that fell short of our expectations in others,” said Kevin Guest, Chairman and Chief Executive Officer. “We are investing across each of our businesses to strengthen their long-term competitive position and made clear progress in key areas. At Hiya, as customer acquisition began responding positively during the quarter, we increased marketing spend to build on that traction, which pressured margins but generated an 18% sequential increase in active subscribers and returned the segment to year-over-year net sales growth. Additionally, our Core Nutritional business expanded its operating margin from a year ago on a leaner cost structure despite lower net sales. While we have more work to do in growing Core Nutritional active customers and net sales at Rise Wellness, we believe we have the right strategies in place.

“In Core Nutritional, rebuilding our active customer base is our top priority and our single largest growth lever. For example, active customers in the Southeast Asia Pacific region grew 3% sequentially in the third quarter, demonstrating what works when our initiatives and execution align. We are evolving our Brand Partner incentive plan to more directly reward growth in active customers, investing in digital marketing to build awareness of the USANA brand, and advancing product innovation that we plan to begin introducing in 2027.

“At Hiya, our investment in customer acquisition is producing encouraging early returns. Notably, Hiya added approximately 29,500 net active monthly subscribers sequentially, customer acquisition costs declined noticeably from the first half of the year and net sales through Target and Amazon more than doubled from the second quarter. Because Hiya is predominantly a subscription business today, the subscribers we add support results in future quarters. Additionally, Hiya continues to make progress in broadening its reach beyond direct-to-consumer, and we look forward to providing updates in early 2027.

“At Rise Wellness, we are building on a strengthening retail foundation and working towards improved margins. As planned, we launched Protein Pop Balance nationally at Target and online in September, and Target sales grew strongly from the second quarter. Our focus is converting this progress into consistent, profitable growth.”

Q3 2026 Segment Results

Core Nutritional

Core Nutritional
Q3 2026 Year-Over-Year Year-Over-Year (Constant Currency) Sequentially
Net Sales $171 million -3% -6% -11%
Active Customers 356,000 -8% N/A -7%
Asia Pacific Region
Q3 2026 Year-Over-Year Year-Over-Year (Constant Currency) Sequentially
Net Sales $138 million -1% -4% -12%
Active Customers 283,000 -8% N/A -8%
Asia Pacific Sub-Regions
Q3 2026 Year-Over-Year Year-Over-Year (Constant Currency) Sequentially
Greater China Net Sales $94 million +1% -3% -18%
Active 192,000 -9% N/A -11%
Customers
North Asia Net Sales $14 million -20% -18% +3%
Active 30,000 -19% N/A -6%
Customers
Southeast Asia Pacific Net Sales $30 million +2% +2% +4%
Active 61,000 Flat N/A +3%
Customers
Americas and Europe Region
Q3 2026 Year-Over-Year Year-Over-Year (Constant Currency) Sequentially
Net Sales $33 million -11% -12% -5%
Active Customers 73,000 -9% N/A -5%

Hiya Health

Q3 2026 Year-Over-Year Sequentially
Net Sales $32 million +2% +12%
Active Monthly Subscribers 195,500 +1% +18%

Rise Wellness

Q3 2026 Year-Over-Year Sequentially
Net Sales $4 million -45% +7%

Balance Sheet

The Company ended the quarter with $179 million in cash and cash equivalents and zero debt. As of October 3, 2026, inventory totaled $93 million, a decrease of approximately $14 million, or 13%, compared to balances at year-end 2025.

The Company did not repurchase any shares during the quarter and has approximately $34 million remaining under the current share repurchase authorization as of the end of the third quarter.

Fiscal Year 2026 Outlook

The Company is updating its outlook for fiscal year 2026, as follows:

Fiscal Year 2026 Outlook
Updated Estimate Previous Estimate
Core Nutritional business net sales $740 million* $750 million
Hiya net sales $130 million $125 million
Rise Wellness net sales $30 million $35 million
Consolidated net sales Approaching $900 million $910 million
Net (loss) earnings $(16) million $(11) million
Diluted EPS $(0.90) $(0.61)
Adjusted diluted EPS(1) $0.55 $0.76
Adjusted EBITDA(2) $77 million $80.5 million†
* Reflects an expected favorable currency exchange rate impact of approximately $20 million, or 2% of net sales and one less week of operations compared to fiscal year 2025, which was a 53-week year.
† As corrected; previously published as $87 million on August 4, 2026. See “Correction of Previously Reported Adjusted EBITDA Attributable to USANA” below.

“Consolidated net sales declined 4% in the third quarter, as growth at Hiya was more than offset by lower sales in Core Nutritional and Rise,” said Doug Hekking, Chief Financial Officer. “We made progress on improving profitability in our Core Nutritional segment during the quarter, while we chose to increase investment at Hiya to accelerate subscriber growth, which weighed on margins in the quarter but produced strong growth in active monthly subscribers.

“We generated $8 million of free cash flow(3) in the quarter and $36 million year-to-date, reduced inventory 13% from year-end, and ended the period with $179 million in cash and no debt. That financial strength gives us the flexibility to continue investing in the initiatives we expect to drive future growth across our businesses, including our omnichannel strategy, while maintaining financial discipline.

“We are updating our fiscal 2026 outlook to consolidated net sales approaching $900 million and Adjusted EBITDA of $77 million. Compared with our prior outlook, as corrected, the change reflects lower expectations for Rise Wellness and our deliberate decision to invest resources at Hiya to drive increased active monthly subscribers, partially offset by stronger profitability in Core Nutritional. We expect continued sequential progress from Hiya during the fourth quarter on both net sales and Adjusted EBITDA. While these investments constrain near-term results, we believe they set the stage for renewed growth across our businesses, and we plan to enter 2027 with a strong balance sheet and clear priorities to deliver it.”

Correction of Previously Reported Adjusted EBITDA Attributable to USANA

In preparing its third quarter results, the Company identified an omission in its second quarter 2026 reconciliation of net (loss) earnings to Adjusted EBITDA attributable to USANA. The $29.1 million Hiya goodwill impairment was added back in full, rather than net of the $6.2 million share attributable to the noncontrolling interest. This correction affects Adjusted EBITDA attributable to USANA, a non-GAAP measure, and had no effect on the Company’s reported GAAP results. Corrected amounts are as follows:

Adjusted EBITDA attributable to USANA As previously reported Correction As corrected
Second quarter 2026 $ 27.8 $ (6.2) $ 21.7
Fiscal 2026 outlook (August 4, 2026) 86.7 (6.2) 80.5
$ in millions
Sequential comparisons and the previous outlook presented in this release reflect the corrected amounts. Amounts may not sum due to rounding.
____________________
(1) Adjusted Diluted (Loss) Earnings Per Share is a non-GAAP financial measure. The Company excludes cost realignment expenses, impairment expense, gain on sale of assets, and acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition-related intangible assets in calculating Adjusted Diluted (Loss) Earnings Per Share. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Diluted Loss Per Share (GAAP) to Adjusted Diluted Loss Per Share (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(3) Free cash flow is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net Cash Provided by (Used in) Operating Activities (GAAP) to Free Cash Flow (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.

Non-GAAP Financial Measures

This press release contains the non-GAAP financial measures Adjusted EBITDA, Adjusted Diluted EPS and free cash flow. Adjusted EBITDA is a non-GAAP financial measure of (loss) earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net (loss) earnings. Adjusted Diluted EPS is a non-GAAP financial measure of diluted (loss) earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

Adjusted EBITDA (non-GAAP) is net (loss) earnings (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization (including right-of-use asset reduction), non-cash share-based compensation, transaction-related expenses and integration costs for the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest related to Hiya.

Adjusted diluted (loss) earnings per share (non-GAAP) is diluted (loss) earnings per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses and integration costs related to the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets.

Free cash flow (non-GAAP) is net cash provided by (used in) operating activities (its most directly comparable GAAP financial measure) less purchases of property and equipment. Management believes free cash flow is a useful measure of the cash the business generates, after investing in property and equipment, that is available for strategic investments, share repurchases and other uses.

Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), Adjusted diluted (loss) earnings per share (non-GAAP), and free cash flow (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”) and investors should not directly compare with or infer a relationship from any of the Company’s operating results presented in accordance with GAAP to Adjusted EBITDA, Adjusted diluted (loss) earnings per share and free cash flow. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for, financial information presented in accordance with GAAP.

Reconciliation of Net Loss (GAAP) to Adjusted EBITDA (non-GAAP) (in thousands)
Quarter ended
October 3, 2026 September 27, 2025
Net loss attributable to USANA (GAAP) $ (5,556 ) $ (6,522 )
Net loss attributable to noncontrolling interest (1,334 ) (140 )
Net loss $ (6,890 ) $ (6,662 )
Adjustments:
Income taxes $ 6,086 $ 8,456
Interest (income) expense, net (607 ) (529 )
Depreciation and amortization 5,212 5,112
Amortization of intangible assets - Hiya 4,455 4,455
Earnings before interest, taxes, depreciation, and amortization (EBITDA) $ 8,256 $ 10,832
Add EBITDA adjustments:
Non-cash share-based compensation 3,404 3,576
Transaction, integration and transition costs - Hiya — 179
Adjusted EBITDA 11,660 14,587
Adjusted EBITDA attributable to noncontrolling interest 392 (803 )
Adjusted EBITDA attributable to USANA $ 12,052 $ 13,784
Reconciliation of Diluted Loss Per Share (GAAP) to Adjusted Diluted Loss Per Share (non-GAAP) (in thousands, except per share data)
Quarter ended
October 3, 2026 September 27, 2025
Net loss attributable to USANA (GAAP) $ (5,556 ) $ (6,522 )
Loss per common share - Diluted $ (0.30 ) $ (0.36 )
Weighted Average common shares outstanding - Diluted 18,498 18,293
Adjustment to net loss:
Transaction, integration and transition costs - Hiya $ — $ 179
Amortization of intangible assets - Hiya 4,455 4,455
Adjustments to net loss attributable to noncontrolling interest (942 ) (942 )
Adjusted net loss attributable to USANA $ (2,043 ) $ (2,830 )
Adjusted loss per common share - Diluted $ (0.11 ) $ (0.15 )
Weighted average common shares outstanding - Diluted 18,498 18,293
Reconciliation of Net Cash Provided by (Used in) Operating Activities (GAAP) to Free Cash Flow (non-GAAP) (in thousands)
Quarter ended Nine months ended
October 3, 2026 September 27, 2025 October 3, 2026 September 27, 2025
Net cash provided by (used in) operating activities (GAAP) $ 11,965 $ (1,961 ) $ 45,043 $ 25,739
Less: Purchases of property and equipment (3,522 ) (3,198 ) (9,322 ) (11,028 )
Free cash flow (non-GAAP) $ 8,443 $ (5,159 ) $ 35,721 $ 14,711

Management Commentary Document and Conference Call

Prompts

USANA Health Sciences, Inc. (ticker USNA), listed in United States.

Company History

Date Change Detail
Aug 15, 2000 Renamed USANA INC → USANA HEALTH SCIENCES INC

ETFs Holding USANA Health Sciences, Inc.

ETF Weight in ETF Shares Market value As of
SQLV 0.30% 3,971 $ 84.781K Jun 30, 2026
AFSM 0.18% 19,399 $ 262.662K Nov 16, 2026
VFVA 0.08% 52,306 $ 745.884K Aug 31, 2026
BSVO 0.04% 78,562 $ 1.07M Nov 18, 2026
VFQY 0.02% 7,200 $ 102.672K Aug 31, 2026
SFGV 0.02% 12,801 $ 170K Nov 18, 2026
DFSV 0.01% 242,776 $ 3.091M Nov 12, 2026
AVUV 0.01% 158,360 $ 2.144M Nov 16, 2026
AVSC 0.01% 18,388 $ 248.974K Nov 16, 2026
DFAS 0.00% 124,834 $ 1.589M Nov 12, 2026
DFAT 0.00% 109,886 $ 1.399M Nov 12, 2026
DXUV 0.00% 10,875 $ 138.439K Nov 12, 2026
DFAC 0.00% 52,979 $ 674.423K Nov 12, 2026
DCOR 0.00% 18,998 $ 241.845K Nov 12, 2026
DFAU 0.00% 2,020 $ 25.715K Nov 12, 2026
DFUS 0.00% 1,784 $ 22.71K Nov 12, 2026
AVUS 0.00% 5,468 $ 74.037K Nov 16, 2026
AVSU 0.00% 247 $ 3,344.38 Nov 16, 2026